Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET-D: Vitamin D Normalization in Myocardial Infarction Patients
NCT02996721Phase 4Completed
- Sponsor
- Intermountain Health
- Start
- Apr 2017
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vitamin d in myocardial infarction (MI) (2 arms), sponsored by Intermountain Health. Primary endpoint: Composite Outcome of Death, Myocardial Infarction, Heart Failure Hospitalization, and Cerebral Vascular Accident at 48 months. Started Apr 2017; status: completed.
02
Drugs
vitamin d
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on NCT02996721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996721.